Indian Pharmaceutical Alliance

The $32-billion generic-driven Indian pharma industry is eyeing a sea of opportunities as global demand for safe and quality drugs rises.

The Delhi High Court has said that for now, a government ban on popular cough syrup Corex, made by US pharma Pfizer, will not hold. The court will next hear the case on Monday.

Government's move will adversely impact patients' interest, say experts.

The government has revised its list of essential medicines to add drugs for diseases ranging from cancer and HIV/AIDS to hepatitis C, in a move aimed at making them more affordable.

With 32 of top 100 pharmaceutical firms not responding to its direction to register for online database, the National Pharmaceutical Pricing Authority (NPPA) has asked pharma associations to ask their members to register immediately.

After failing to get a stay order from the Delhi High Court on the latest round of drug price control order, the pharmaceuticals industry has called for a dialogue with the regulators to resolve the row, saying such issues are best ironed out through dialogues than in court rooms.

A new drug price control policy at long last, restrictions on multinationals taking over domestic firms and India cracking down on foreign firms' patents marked the year 2012 for the country's $22 billion pharmaceutical sector.

Prices of various leading drug brands will come down by up to 80 per cent thanks to the newly-approved National Pharmaceutical Pricing Policy but at the same time it will hurt investment sentiments in the country's pharmaceutical sector, according to industry bodies.

The $32-billion generic-driven Indian pharma industry is eyeing a sea of opportunities as global demand for safe and quality drugs rises.

The Delhi High Court has said that for now, a government ban on popular cough syrup Corex, made by US pharma Pfizer, will not hold. The court will next hear the case on Monday.

Government's move will adversely impact patients' interest, say experts.

The government has revised its list of essential medicines to add drugs for diseases ranging from cancer and HIV/AIDS to hepatitis C, in a move aimed at making them more affordable.

With 32 of top 100 pharmaceutical firms not responding to its direction to register for online database, the National Pharmaceutical Pricing Authority (NPPA) has asked pharma associations to ask their members to register immediately.

After failing to get a stay order from the Delhi High Court on the latest round of drug price control order, the pharmaceuticals industry has called for a dialogue with the regulators to resolve the row, saying such issues are best ironed out through dialogues than in court rooms.

A new drug price control policy at long last, restrictions on multinationals taking over domestic firms and India cracking down on foreign firms' patents marked the year 2012 for the country's $22 billion pharmaceutical sector.

Prices of various leading drug brands will come down by up to 80 per cent thanks to the newly-approved National Pharmaceutical Pricing Policy but at the same time it will hurt investment sentiments in the country's pharmaceutical sector, according to industry bodies.